Seongnam, South Korea

Jae-Ha Ryu

This inventor holds 1 USPTO granted patent. Top assignee: Dongwha Pharm. Ind. Co., Ltd.. Active years: 2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jae-Ha Ryu. Retrieved from https://idiyas.com/inventor/jae-ha-ryu-ovx1k0uq

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2000

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jae-Ha Ryu: Innovator in Pharmaceutical Chemistry

Introduction

Jae-Ha Ryu is a notable inventor based in Seongnam, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on benzoisoxazole derivatives.

Latest Patents

Jae-Ha Ryu holds a patent for "3-amino-1,2-benzoisoxazole derivatives, process for preparation, and use." This patent highlights his expertise in developing new chemical compounds that have potential applications in medicine.

Career Highlights

Ryu is currently employed at Dongwha Pharm. Ind. Co., Ltd., where he continues to advance his research and development efforts. His work at this company has positioned him as a key player in the pharmaceutical industry.

Collaborations

He collaborates with talented coworkers, including Yong-Nam Han and Sung-June Yoon, who contribute to his projects and enhance the innovative environment at Dongwha Pharm.

Conclusion

Jae-Ha Ryu's contributions to pharmaceutical chemistry through his patents and collaborations underscore his role as an influential inventor in the industry. His work continues to pave the way for advancements in medical applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…